BR112013019628B8 - conjugados de peg-carboidrato-lipídeo - Google Patents

conjugados de peg-carboidrato-lipídeo Download PDF

Info

Publication number
BR112013019628B8
BR112013019628B8 BR112013019628A BR112013019628A BR112013019628B8 BR 112013019628 B8 BR112013019628 B8 BR 112013019628B8 BR 112013019628 A BR112013019628 A BR 112013019628A BR 112013019628 A BR112013019628 A BR 112013019628A BR 112013019628 B8 BR112013019628 B8 BR 112013019628B8
Authority
BR
Brazil
Prior art keywords
carbohydrate
functional groups
peg
lipid conjugates
lipid
Prior art date
Application number
BR112013019628A
Other languages
English (en)
Other versions
BR112013019628B1 (pt
BR112013019628A2 (pt
Inventor
Wu Nian
Original Assignee
Wu Nian
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wu Nian filed Critical Wu Nian
Publication of BR112013019628A2 publication Critical patent/BR112013019628A2/pt
Publication of BR112013019628B1 publication Critical patent/BR112013019628B1/pt
Publication of BR112013019628B8 publication Critical patent/BR112013019628B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/25—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00—Applications
    • C08L2203/02—Applications for biomedical use

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

resumo "conjugados de polímero-carboidrato-lipídeo" a presente invenção compreende compostos, métodos de fabricação e métodos de utilização. os compostos podem ter uma cadeia principal e três grupos funcionais ramificados: um lipídeo, um polímero hidrofílico e um carboidrato. os grupos funcionais específicos podem ser selecionados para aplicações específicas em formulações de produtos farmacêuticos, cosméticos, nutracêuticos e similares. uma variedade de ligantes entre a cadeia principal e os grupos funcionais também pode ser selecionada para otimizar o desempenho.
BR112013019628A 2011-02-08 2012-02-03 conjugados de peg-carboidrato-lipídeo BR112013019628B8 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161440488P 2011-02-08 2011-02-08
US61/440,488 2011-02-08
US13/354,726 US20120202890A1 (en) 2011-02-08 2012-01-20 Polymer-carbohydrate-lipid conjugates
US13/354,726 2012-01-20
US13/364,967 US9175027B2 (en) 2011-02-08 2012-02-02 Polymer-carbohydrate-lipid conjugates
US13/364,967 2012-02-02
PCT/US2012/023844 WO2012109112A2 (en) 2011-02-08 2012-02-03 Polymer-carbohydrate-lipid conjugates

Publications (3)

Publication Number Publication Date
BR112013019628A2 BR112013019628A2 (pt) 2016-10-04
BR112013019628B1 BR112013019628B1 (pt) 2020-03-10
BR112013019628B8 true BR112013019628B8 (pt) 2020-04-07

Family

ID=46601060

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013019628A BR112013019628B8 (pt) 2011-02-08 2012-02-03 conjugados de peg-carboidrato-lipídeo

Country Status (9)

Country Link
US (2) US20120202890A1 (pt)
EP (1) EP2673000B1 (pt)
JP (1) JP5934255B2 (pt)
CN (1) CN104704023B (pt)
BR (1) BR112013019628B8 (pt)
CA (1) CA2826468C (pt)
ES (1) ES2674885T3 (pt)
MX (1) MX352252B (pt)
WO (2) WO2012109052A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883177B2 (en) * 2011-06-28 2014-11-11 Nian Wu Pharmaceutical compositions for parenteral administration
WO2014055941A2 (en) * 2012-10-04 2014-04-10 Pappalardo Juan Sabastian Compounds and methods for targeted immune system delivery
ES2670969T3 (es) 2012-11-13 2018-06-04 Adocia Formulación de acción rápida de insulina que comprende un compuesto aniónico sustituido
WO2014076422A1 (fr) * 2012-11-13 2014-05-22 Adocia Composes anioniques substitues constitues d'un squelette forme d'un nombre discret d'unites saccharidiques
CN113274506A (zh) * 2013-12-05 2021-08-20 念·吴 聚合物-碳水化合物的缀合物的药物转递技术
US10064954B2 (en) * 2015-06-23 2018-09-04 Nian Wu Polymer-cyclodextrin-lipid conjugates
WO2016209732A1 (en) 2015-06-23 2016-12-29 Wu Nian Polymer-cyclodextrin-lipid conjugates
WO2017053991A1 (en) * 2015-09-25 2017-03-30 University Of Notre Dame Du Lac Nanoallergens and uses thereof
US10687528B2 (en) 2017-12-12 2020-06-23 International Business Machines Corporation Antimicrobial polymers with enhanced functionalities
US10653142B2 (en) 2017-12-12 2020-05-19 International Business Machines Corporation Polymers with antimicrobial functionalities
US10687530B2 (en) 2017-12-12 2020-06-23 International Business Machines Corporation Hydrophilic polymers with antimicrobial functionalities
US10836864B2 (en) 2017-12-12 2020-11-17 International Business Machines Corporation Chemical compositions with antimicrobial functionality
US10667514B2 (en) 2017-12-12 2020-06-02 International Business Machines Corporation Antimicrobial ionene compositions with a variety of functional groups
US10743537B2 (en) 2017-12-12 2020-08-18 International Business Machines Corporation Monomer compositions with antimicrobial functionality
US10595527B2 (en) 2017-12-12 2020-03-24 International Business Machines Corporation Antimicrobial polymers capable of supramolecular assembly
JP2021506905A (ja) * 2017-12-21 2021-02-22 コーメディクス・インコーポレーテッド 血液中のＣａｎｄｉｄａ ａｕｒｉｓを処置するための方法および医薬組成物
AU2019377525A1 (en) * 2018-11-09 2021-05-27 Translate Bio, Inc. Multi-PEG lipid compounds
WO2020139851A1 (en) * 2018-12-26 2020-07-02 Clear Lake Research, Llc Delivery of health benefits through component formulation

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL142650A (en) 1998-04-08 2007-06-03 Galmed Int Ltd Use of bile acid conjugates or bile salts and fatty acids or fatty acids in the preparation of pharmaceuticals for lowering cholesterol, for the treatment of fatty liver and for the treatment of hyperglycemia and diabetes
US6309633B1 (en) * 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
US20030212051A1 (en) 2001-04-06 2003-11-13 Polli James E Bile acid containing prodrugs with enhanced bioavailabilty
DE10209822A1 (de) * 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
US20030215395A1 (en) * 2002-05-14 2003-11-20 Lei Yu Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier
JP4723380B2 (ja) * 2003-09-25 2011-07-13 テルモ株式会社 ポリエチレングリコール誘導体及びこれを膜構成成分とする薬物担体
WO2006050072A2 (en) * 2004-10-29 2006-05-11 Neopharm, Inc. Manufacturing process for liposomal preparations
AU2007347182A1 (en) * 2006-09-15 2008-08-21 The Burnham Institute High affinity EphB receptor binding compounds and methods of use thereof
EP2389156A1 (en) 2009-01-23 2011-11-30 Brian Charles Keller Peg-lipid conjugates for increasing the solubility of drug compounds
WO2010107487A2 (en) 2009-03-18 2010-09-23 Wu Nian Lipid-drug conjugates for drug delivery
CA2755963C (en) * 2009-03-20 2019-04-02 Egen, Inc. Polyamine derivatives
JP2012528857A (ja) * 2009-06-02 2012-11-15 ウー，ニエン 純粋ｐｅｇ−脂質コンジュゲート
WO2011005980A1 (en) 2009-07-09 2011-01-13 Intradigm Corporation Novel heterobifunctional polyethylene glycol reagents, their preparation and uses thereof

Also Published As

Publication number Publication date
BR112013019628B1 (pt) 2020-03-10
CA2826468C (en) 2018-11-27
WO2012109112A2 (en) 2012-08-16
WO2012109052A1 (en) 2012-08-16
EP2673000B1 (en) 2018-05-16
JP5934255B2 (ja) 2016-06-15
US9175027B2 (en) 2015-11-03
WO2012109112A4 (en) 2013-03-07
CN104704023B (zh) 2016-10-19
US20120202890A1 (en) 2012-08-09
EP2673000A2 (en) 2013-12-18
CN104704023A (zh) 2015-06-10
ES2674885T3 (es) 2018-07-04
US20120202979A1 (en) 2012-08-09
CA2826468A1 (en) 2012-08-16
MX352252B (es) 2017-11-15
WO2012109112A3 (en) 2013-01-17
JP2014504649A (ja) 2014-02-24
MX2013009128A (es) 2013-10-03
BR112013019628A2 (pt) 2016-10-04

Similar Documents

Publication Publication Date Title
BR112013019628B8 (pt) conjugados de peg-carboidrato-lipídeo
CU20200089A7 (es) Moléculas de unión contra bcma
BR112015027322A8 (pt) Compostos antissenso conjugados e sua utilização
BR112014011594A2 (pt) anticorpos anti-il-36r
BR112014003273A8 (pt) espessantes associativos com base nos polímeros hiper-ramificados
BR112015009228A2 (pt) soluções estáveis anti-inflamatórias e midriáticas livres de conservantes para injeção
BR112014024903A2 (pt) anticorpos biespecíficos contra tweak humanao e il17 humana e seus usos
BR112013020767A2 (pt) composições compreendendo ácido peróxi alfa-cetocarboxílico e métodos para a produção e o uso do mesmo
BR112014013175A8 (pt) composições de liberação prolongada baseadas em lipídios anfipáticos e processo para preparar comprimidos de composição de liberação prolongada
BR112012024312A2 (pt) anticorpos biespecíficos
BR112015004875A2 (pt) formulações de anticorpo e seus usos
ECSP12012208A (es) Formulaciones orales y sales lipofílicas de metilnaltrexona
BR112012032008A2 (pt) anticorpos s100a4 e usos terapêuticos do mesmo
BR112014005935A2 (pt) derivados de anilina, sua preparação e sua aplicação terapêutica
CO7250444A2 (es) Uso de seaprose para eliminar biopelículas bacterianas
BR112013008749A2 (pt) análogos de ciclosporina
ECSP13012531A (es) Conjugado de naloxol-peg cristalino
BR112015000494A2 (pt) matriz e composições da camada para a proteção dos biotivos
BR112015000188A2 (pt) isolados de proteína de batata
BR112015008389A2 (pt) compostos úteis na síntese de compostos de benzamida
CO6920289A2 (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib.
BR112014004263A2 (pt) composições fixadoras de cabelo
BR112014013327A2 (pt) composições para cuidado oral
BR112014029874A8 (pt) composição farmacêutica do tipo emulsão óleo em água, composições e uso da composição farmacêutica
BR112014016804A8 (pt) composições, métodos de uso e métodos de tratamento

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B06U Preliminary requirement: requests with searches performed by other patent offices: suspension of the patent application procedure
B09A Decision: intention to grant
B16A Patent or certificate of addition of invention granted

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/02/2012, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant

Free format text: REF. RPI 2566 DE 10/03/2020 QUANTO AOS DESENHOS.